AP NEWS

Eyenovia to Participate in Panel Presentation at OSN New York 2018

September 19, 2018

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, has been invited to participate in a panel discussion at the upcoming Ocular Surgery News (OSN) New York 2018 Conference, being held September 28-30 in New York, N.Y.

Dr. Ianchulev will be joined by fellow leaders in the ophthalmology and optometry community to present cases and discuss the medical and surgical management of front-of-the-eye conditions, complications and new technologies addressing these issues.

“Each year OSN New York provides an intimate platform for innovators in the eye care community to come together and provide thoughtful discussion on both our common and unique challenges,” commented Dr. Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer. “I look forward to participating in this year’s industry panel session to discuss these as well as opportunities in treating eye conditions, select case studies demonstrating significant unmet patient needs and new approaches to developing ophthalmic drugs, including the use of Eyenovia’s high-precision microdosing technology.”

Details of the Panel Presentation:

Presentation: Medical and Surgical Management of Corneal Conditions and Complications Presenter(s): Kenneth A. Beckman, MD, FACS; D. Rex Hamilton, MD, MS, FACS; Kathryn M. Hatch, MD; Sean Ianchulev, MD, MPH; Sumitra Khandelwal, MD; Francis S. Mah, MD; Tal Raviv, MD, FACS; Christopher E. Starr, MD, FACS; Mitchell P. Weikert, MD Moderator: Terry Kim, MD Date/Time: Friday, September 28 at 11:40-12:40 p.m. EDT Location: The Sheraton New York Times Square Hotel

About EyenoviaEyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma and other eye diseases.

Company Contact:Eyenovia, Inc.John GandolfoChief Financial Officer jgandolfo@eyenoviabio.com

Investor Contact:Tram Bui / Alexander LoboThe Ruth GroupPhone: 646-536-7035/7037 tbui@theruthgroup.com / alobo@theruthgroup.com

Media Contact:The Ruth GroupKirsten Thomas508-280-6592 kthomas@theruthgroup.com

AP RADIO
Update hourly